[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]

• STADA makes one of the largest financial investments in the Ukrainian pharmaceutical sector to date and one of the biggest business investments in Ukraine recently.
• Biopharma?s pharmaceutical business will become an integral part of STADA?s Ukrainian organization and has strong growth potential in high-quality prescription and consumer healthcare products.
• STADA CEO Peter Goldschmidt: ?With this acquisition, we will become an important player in the Ukrainian pharma market with a strong local production footprint.?

Bad Vilbel, December 2, 2019 ??The STADA Group, a global manufacturer of high-quality generic drugs and consumer healthcare products, continues its growth trajectory in Europe. The company, headquartered in Germany, announced today that it is acquiring the pharmaceutical business of Biopharma, one of the key pharmaceutical producers in Ukraine. This also includes production facilities in the city of Bila Tserkva, in the Kiev region. Biopharma shareholders will retain the company?s plasma business and will focus on its development both in Ukraine and abroad. The acquisition is subject to customary conditions precedent, including merger clearance in Ukraine, and is expected to close in December 2019. As a result of this acquisition, STADA has made one of the largest financial investments in the Ukrainian pharmaceutical sector to date and one of the biggest recent foreign investments in this country. ?We see great potential in the Ukrainian market. With this acquisition, we will become an important player in the Ukrainian pharma market with a strong local production footprint,? emphasizes STADA CEO Peter Goldschmidt. ?STADA?s acquisition of the pharmaceutical business of Biopharma is a logical step within STADA?s European growth strategy. We will integrate Ukraine as soon as possible into our European organization,? explains Steffen Wagner, Head of European Markets at STADA. STADA?s Ukrainian business will be headed by the newly appointed General Manager Borys Labensky. ?My goal is to integrate the business quickly into our Group, drive synergies and leverage the capacity of the acquired production plant,? he said. Peter Goldschmidt welcomes around 300 new colleagues to the STADA family: ?Our four corporate values of Agility, Entrepreneurship, Integrity, and One STADA form the basis for a growth culture for all our employees globally.? Konstantin Efimenko, Biopharma?s Managing Partner: ?Biopharma is a leading pharmaceutical company founded over 100 years ago and expanding rapidly since 2014, building two state-of-the-art, GMP-certified facilities in Bila Tserkva. We offer high-quality engineering, a skilled, professional team and high production standards monitored through international audits. Attracting such a high-quality European investor demonstrates confidence in our employees and capabilities, and will reinforce our ability to deliver high-quality and innovative products to patients. Together with my partner Mr. Vasyl Khmelnytskiy and financial investors, I will focus on Biopharma?s plasma business, leveraging our new plasma fractionation plant, developing a network of modern blood collection centers and expanding our presence on international markets.? Lenna Koszarny, Founding Partner and CEO of Horizon Capital: ?As the leading private equity firm in Ukraine, we are proud to back Biopharma since 2012, investing together with Dutch development bank FMO into this exciting growth story. We believed in Biopharma?s shareholders and their bold vision to build a best-in-class pharmaceutical plant and a plasma fractionator, requiring capital investments in excess of $100 million. We welcome STADA?s acquisition of Biopharma?s pharmaceutical business and their decision to invest and produce in Ukraine?. STADA?s acquisition of Biopharma?s pharmaceutical prescription and consumer health business represents the latest milestone in a series of smaller bolt-on acquisitions with significant strategic value, including STADA?s previously-announced purchase of six GSK OTC products in August 2019 and its acquisitions of the EMEA distribution rights to Nizoral and controlling stakes in Vietnam-based Pymepharco and BIOCEUTICALS in 2018. The transaction is subject to merger control in Ukraine and is expected to close later this year.   Forward-looking statement This announcement may include projections and other ?forward-looking? statements within the meaning of applicable securities laws. You should not place undue reliance on forward-looking statements and we do not undertake publicly to update or revise any forward-looking statement that may be made herein, whether as a result of new information, future events or otherwise. About STADA Arzneimittel AG STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a two pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2018, STADA achieved adjusted Group sales of EUR 2,330.8 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 503.5 million. As of December 31, 2018, STADA employed 10,416 people worldwide. Additional information for journalists STADA Arzneimittel AG / Media Relations / Stadastrasse 2-18 / 61118 Bad Vilbel ? Germany / Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: press@stada.de Additional information for capital market participants STADA Arzneimittel AG / Investor & Creditor Relations / Stadastrasse 2-18 / 61118 Bad Vilbel ? Germany / Phone: +49 (0) 6101 603-4689 / Fax: +49 (0) 6101 603-215 / E-mail: ir@stada.de